CEBAM | ACP | HAS | KDIGO | KHA-CARI | BCMA | UMHS | VA-DoD | NICE | ||
---|---|---|---|---|---|---|---|---|---|---|
2012 | 2013 | 2013 | 2013 | 2013 | 2014 | 2014 | 2014 | 2015 | ||
Blood pressure management | ||||||||||
BP monitoring intervals | ▪ | |||||||||
individualized BP targets | ▪ | ▪ | ▪ | |||||||
BP target | < 140/90 | ▪ | ▪ | ▪ | ▪ | ▪ | ▪ | ▪ | ▪ | |
BP target in diabetics | < 140/90 | GP | ||||||||
< 140/80 | ||||||||||
< 130/80 | ▪ | ▪ | ||||||||
BP target in ≥ microalbuminuria | < 140/90 | ▪ | ||||||||
< 130/80 | ▪ | ▪ | i | ▪ | ||||||
medication | renin-angiotensin system antagonist | i ➢ | i | |||||||
ACEI | i | i | i | i | i | ▪ | i | |||
ARB | i | i | i | i | ▪ | i | ||||
combination of ACEI + ARB | – | – | – | – | ||||||
combination of ACEI/ARB + direct renin inhibitor | – | – | – | |||||||
diuretics | i | i | ||||||||
β-blocker | i | i | ||||||||
calcium channel blocker | i | i | ||||||||
side effects | ▪ |